Last reviewed · How we verify
NCT05972200
V5/MT Stimulation on Reading and Reading-related Measures in Developmental Dyslexia
NA trial testing Active HD-tDCS over V5/MT in Developmental Dyslexia in 36 participants. Currently enrolling.
31 August 2026
Quick facts
| Lead sponsor | Bambino Gesù Hospital and Research Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 1 September 2023 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 August 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Active HD-tDCS over V5/MT
- Active HD-tDCS over V1
- Sham HD-tDCS over V5/MT or V1
Conditions studied
- Developmental Dyslexia — all drugs for Developmental Dyslexia →
Sponsor
Bambino Gesù Hospital and Research Institute
Who can join
Adults 8 to 13, any sex, with Developmental Dyslexia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present study grounds on the absence of evidence-based treatment in individuals with developmental dyslexia (DD). At this topic, the present study will explore the potential effect of transcranial direct current stimulation (tDCS) over left hemispheric direct Lateral Geniculate Nucleus (LGN)-V5/MT pathway, cerebral areas usually disrupted in individuals with DD. The investigators hypothesized that active tDCS over V5/MT will boost reading skills in children and adolescents with DD. On the contrary, sham (placebo condition) tDCS over V5/MT or active (control condition) tDCS over V1 will not have significant effect in improving reading skills. Further, both active and sham tDCS will be safe and well tolerated.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Detecting the contribution of V5/MT in reading, reading-related tasks, eye-movements and EEG-oscillations in children and adolescents with developmental dyslexia via high-definition tDCS: a protocol study.
Somma F, Lazzaro G, Rima S, Rainich K, et al · · 2025 · PMID 40624571 · DOI 10.1186/s40359-025-03036-w
Verify or expand the search:
- PubMed search for NCT05972200
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Bambino Gesù Hospital and Research Institute trials
Trials by the same sponsor.
- NCT07297914 — Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL · Phase 2, PHASE3 · not yet recruiting
- NCT07464561 — RESCCUE4 - Group CBT for Social Anxiety in Adolescents · NA · completed
- NCT06080191 — Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL · Phase 1 · recruiting
- NCT06064903 — CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL · Phase 1, PHASE2 · recruiting
- NCT06931730 — Reprogramming Energy Homeostasis in Overweight Individuals Via Exercise, Cognitive, and Social Training · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05972200 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bambino Gesù Hospital and Research Institute
- Last refreshed: 4 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05972200.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing